title: Hyaluronic acid-based nanogel-drug conjugates with enhanced anticancer activity designed for the targeting of CD44-positive and drug-resistant tumors.
abstract: Many drug-resistant tumors and cancer stem cells (CSC) express elevated levels of CD44 receptor, a cellular glycoprotein binding hyaluronic acid (HA). Here, we report the synthesis of nanogel-drug conjugates based on membranotropic cholesteryl-HA (CHA) for efficient targeting and suppression of drug-resistant tumors. These conjugates significantly increased the bioavailability of poorly soluble drugs with previously reported activity against CSC, such as etoposide, salinomycin, and curcumin. The small nanogel particles (diameter 20-40 nm) with a hydrophobic core and high drug loads (up to 20%) formed after ultrasonication and demonstrated a sustained drug release following the hydrolysis of biodegradable ester linkage. Importantly, CHA-drug nanogels demonstrated 2-7 times higher cytotoxicity in CD44-expressing drug-resistant human breast and pancreatic adenocarcinoma cells compared to that of free drugs and nonmodified HA-drug conjugates. These nanogels were efficiently internalized via CD44 receptor-mediated endocytosis and simultaneous interaction with the cancer cell membrane. Anchoring by cholesterol moieties in the cellular membrane after nanogel unfolding evidently caused more efficient drug accumulation in cancer cells compared to that in nonmodified HA-drug conjugates. CHA-drug nanogels were able to penetrate multicellular cancer spheroids and displayed a higher cytotoxic effect in the system modeling tumor environment than both free drugs and HA-drug conjugates. In conclusion, the proposed design of nanogel-drug conjugates allowed us to significantly enhance drug bioavailability, cancer cell targeting, and the treatment efficacy against drug-resistant cancer cells and multicellular spheroids.
authors.affiliation: Center for Drug Delivery and Nanomedicine and Department of Pharmaceutical Sciences, College of Pharmacy, University of Nebraska Medical Center, Omaha, NE 68198-6025, USA.
authors.forename: Xin
authors.initials: X
authors.lastname: Wei
authors.forename: Thulani H
authors.initials: TH
authors.lastname: Senanayake
authors.forename: Galya
authors.initials: G
authors.lastname: Warren
authors.forename: Serguei V
authors.initials: SV
authors.lastname: Vinogradov
mesh_terms: D000970:Antineoplastic Agents / Q000138:chemical synthesis / Q000737:chemistry* / Q000494:pharmacology*; D045744:Cell Line, Tumor; D002784:Cholesterol / Q000737:chemistry; D015195:Drug Design; D019008:Drug Resistance, Neoplasm / Q000187:drug effects*; D006801:Humans; D018960:Hyaluronan Receptors / Q000378:metabolism*; D006820:Hyaluronic Acid / Q000737:chemistry*; D061986:MCF-7 Cells; D008958:Models, Molecular; D015394:Molecular Structure; D000080385:Nanogels; D014411:Neoplastic Stem Cells / Q000187:drug effects* / Q000378:metabolism; D011092:Polyethylene Glycols / Q000737:chemistry*; D011094:Polyethyleneimine / Q000737:chemistry*; D013329:Structure-Activity Relationship
chemical_list: D000970:Antineoplastic Agents; D018960:Hyaluronan Receptors; D000080385:Nanogels; C413692:polyethylene glycol polyethyleneimine nanogel; D011092:Polyethylene Glycols; D011094:Polyethyleneimine; D006820:Hyaluronic Acid; D002784:Cholesterol
references.citation: J Pharmacol Exp Ther. 2007 May;321(2):462-8
references.pmid: 17289839
references.citation: J Colloid Interface Sci. 2011 Jul 1;359(1):318-25
references.pmid: 21492865
references.citation: Biomaterials. 2011 Oct;32(29):7181-90
references.pmid: 21733572
references.citation: Biomaterials. 2012 Feb;33(4):1190-200
references.pmid: 22074664
references.citation: Eur J Cell Biol. 2006 Aug;85(8):699-715
references.pmid: 16822580
references.citation: Nanomedicine (Lond). 2012 Apr;7(4):597-615
references.pmid: 22471722
references.citation: Nat Mater. 2010 Jul;9(7):572-8
references.pmid: 20562880
references.citation: Bioconjug Chem. 2011 Oct 19;22(10):1983-93
references.pmid: 21863885
references.citation: Mol Pharm. 2011 Aug 1;8(4):1233-46
references.pmid: 21696190
references.citation: J Pharm Sci. 1997 Jul;86(7):832-9
references.pmid: 9232525
references.citation: J Biol Chem. 2010 Sep 24;285(39):30170-80
references.pmid: 20663884
references.citation: J Control Release. 2002 Jan 17;78(1-3):165-73
references.pmid: 11772458
references.citation: Biomacromolecules. 2000 Summer;1(2):208-18
references.pmid: 11710102
references.citation: Pharm Res. 2002 Apr;19(4):396-402
references.pmid: 12033370
references.citation: Nat Rev Cancer. 2012 Mar 22;12(4):237-51
references.pmid: 22437869
references.citation: J Control Release. 2012 Aug 20;162(1):111-8
references.pmid: 22709587
references.citation: Biochimie. 1993;75(1-2):35-41
references.pmid: 8504175
references.citation: N Engl J Med. 2006 Sep 21;355(12):1253-61
references.pmid: 16990388
references.citation: Cancer Chemother Pharmacol. 1995;35(5):432-6
references.pmid: 7850926
references.citation: Curr Mol Med. 2008 Dec;8(8):784-804
references.pmid: 19075676
references.citation: Cancer Res. 1995 Sep 1;55(17):3752-6
references.pmid: 7641188
references.citation: Cell. 2009 Aug 21;138(4):645-659
references.pmid: 19682730
references.citation: J Pharm Sci. 2011 Dec;100(12):5206-18
references.pmid: 21850703
references.citation: J Control Release. 2011 Oct 30;155(2):193-9
references.pmid: 21513749
references.citation: ACS Nano. 2012 May 22;6(5):4483-93
references.pmid: 22540892
references.citation: Biomaterials. 2010 Oct;31(28):7386-97
references.pmid: 20598741
references.citation: J Cell Biol. 1999 Aug 23;146(4):843-54
references.pmid: 10459018
references.citation: J Biol Chem. 2001 Sep 14;276(37):35111-22
references.pmid: 11451952
references.citation: Mol Pharm. 2005 Nov-Dec;2(6):449-61
references.pmid: 16323952
references.citation: J Control Release. 2010 Jan 4;141(1):2-12
references.pmid: 19758573
references.citation: Mol Biotechnol. 2010 Nov;46(3):308-16
references.pmid: 20717753
references.citation: Science. 1988 Apr 8;240(4849):177-84
references.pmid: 2451290
references.citation: Polymer Prepr. 2006;47(2):27-28
references.pmid: 19079755
references.citation: Cancer Biol Ther. 2011 Mar 1;11(5):464-73
references.pmid: 21193839
references.citation: Expert Opin Drug Deliv. 2010 Jan;7(1):49-62
references.pmid: 20017660
references.citation: Pharm Res. 1996 Dec;13(12):1838-45
references.pmid: 8987081